Rigel EVP granted 19,497 RSUs in Form 4

Rigel Pharmaceuticals executive Raymond J. Furey reported an equity compensation award in the form of Restricted Stock Units tied to the company’s common stock.

Rhea-AI Filing Summary

Rigel Pharmaceuticals executive Raymond J. Furey reported an equity compensation award in the form of Restricted Stock Units tied to the company’s common stock. The award covers 19,497 shares, reflected as an acquisition with no cash price because it is a grant, not an open-market purchase.

These Restricted Stock Units will vest quarterly over a three-year period, with the first quarterly vesting scheduled for March 31, 2026. Following this award, Furey is shown as having 51,813 shares of common stock in direct ownership, illustrating his ongoing equity alignment with the company.

Insider Trade Summary

Grant/Award: 19,497 shares

Grant/Award 1 txn

Insider Furey Raymond J.

Role EVP, GC, CCO & Corp Sec

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	19,497	$0.00	$0.00

Holdings After Transaction: Common Stock — 51,813 shares (Direct)

Footnotes (1)

1. F1. The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RIGEL PHARMACEUTICALS (RIGL) report for Raymond J. Furey?

Rigel Pharmaceuticals reported that executive Raymond J. Furey received a grant of 19,497 Restricted Stock Units tied to common stock. This award is recorded as an acquisition, reflecting equity compensation rather than an open‑market share purchase or sale.

How many Rigel Pharmaceuticals (RIGL) shares are involved in Raymond J. Furey’s Form 4 filing?

The Form 4 shows 19,497 shares of Rigel Pharmaceuticals common stock underlying a Restricted Stock Unit award. These units represent potential future shares that will be delivered as they vest under the company’s equity compensation plan.

When do Raymond J. Furey’s RIGL Restricted Stock Units begin vesting?

The Restricted Stock Units begin vesting on March 31, 2026, with vesting occurring quarterly over three years. Each quarterly vesting delivers a portion of the total 19,497 units as shares of common stock to the executive.

What is Raymond J. Furey’s ownership in RIGEL PHARMACEUTICALS after this Form 4 transaction?

After the reported equity award, Raymond J. Furey is shown holding 51,813 shares of Rigel Pharmaceuticals common stock directly. This figure reflects his ownership following the grant of 19,497 Restricted Stock Units recorded in the Form 4 filing.

Did Raymond J. Furey buy or sell RIGEL PHARMACEUTICALS (RIGL) shares on the market?

The Form 4 does not show a market trade; it records an equity award. The 19,497 shares are tied to a Restricted Stock Unit grant, categorized as a grant or award acquisition, with no purchase price listed per share.

How do the RIGL Restricted Stock Units granted to Raymond J. Furey vest over time?

The 19,497 Restricted Stock Units vest in equal quarterly installments over three years. Starting March 31, 2026, a portion of the units converts into common shares each quarter, aligning compensation with longer‑term company performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 05:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Furey Raymond J.

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GC, CCO & Corp Sec

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		19,497(1)	A	$0	51,813	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.

	/s/ Raymond Furey	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.